These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9229742)

  • 1. [Value of tumor markers for screening and diagnosis (except prognostic and surveillance values) in primary bronchial cancers].
    Grivaux M
    Rev Mal Respir; 1997 Apr; 14 Suppl 3():S15-9. PubMed ID: 9229742
    [No Abstract]   [Full Text] [Related]  

  • 2. [Which tumor markers should be used in primary bronchial cancers?].
    Schuller MP; Carrat F; Urban T; Lebeau B
    Rev Mal Respir; 1997 Apr; 14 Suppl 3():S9-14. PubMed ID: 9229750
    [No Abstract]   [Full Text] [Related]  

  • 3. [Value of tumor markers in surveillance of primary bronchial cancers and to evaluate therapy].
    Sculier JP
    Rev Mal Respir; 1997 Apr; 14 Suppl 3():S23-6. PubMed ID: 9229744
    [No Abstract]   [Full Text] [Related]  

  • 4. [Value of serial tumor markers for the detection of recurrences].
    Quoix E
    Rev Mal Respir; 1997 Apr; 14 Suppl 3():S27-9. PubMed ID: 9229745
    [No Abstract]   [Full Text] [Related]  

  • 5. [Value of serial tumor markers for determining the prognosis and predicting treatment response and survival].
    Souquet PJ
    Rev Mal Respir; 1997 Apr; 14 Suppl 3():S20-2. PubMed ID: 9229743
    [No Abstract]   [Full Text] [Related]  

  • 6. [Tumor markers used in diagnosis and monitoring of primary bronchopulmonary carcinoma].
    Mahler B
    Pneumologia; 2008; 57(3):175-7. PubMed ID: 18998332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CYFRA 21-1].
    Pujol JL
    Rev Mal Respir; 1997 Apr; 14 Suppl 3():S31-6. PubMed ID: 9229747
    [No Abstract]   [Full Text] [Related]  

  • 8. [Tumor markers in the diagnosis and follow-up assessment of bronchial carcinoma].
    Fischbach W
    Dtsch Med Wochenschr; 1989 May; 114(20):800-5. PubMed ID: 2656177
    [No Abstract]   [Full Text] [Related]  

  • 9. [In suspected bronchial cancer are the tumor markers neuron-specific enolase, carcinoembryonic antigen and squamous cell carcinoma antigen, of diagnostic help?].
    Jany B; Fischbach W; Chowanetz W
    Med Klin (Munich); 1988 Feb; 83(4):121-4, 158. PubMed ID: 3367874
    [No Abstract]   [Full Text] [Related]  

  • 10. [Neuron specific enolase].
    Milleron B
    Rev Mal Respir; 1997 Apr; 14 Suppl 3():S36-7. PubMed ID: 9229748
    [No Abstract]   [Full Text] [Related]  

  • 11. Diagnostic value of CEA, CYFRA 21-1, NSE and CA 125 assay in serum and pleural effusion of patients with lung cancer.
    Wu GP; Ba J; Zhao YJ; Wang EH
    Acta Cytol; 2007; 51(4):679-80. PubMed ID: 17718156
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical significance of tumor markers CYFRA 21-1 and neuron-specific enolase in lung cancer].
    Kushlinskiĭ NE; Liubimova NV; Lemeshko AO; Vasil'ev AV; Davydov MI
    Biull Eksp Biol Med; 1997 Jan; 123(1):98-100. PubMed ID: 9213472
    [No Abstract]   [Full Text] [Related]  

  • 13. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic markers for stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N
    Lung Cancer; 2008 Feb; 59(2):274-5. PubMed ID: 18055061
    [No Abstract]   [Full Text] [Related]  

  • 15. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer.
    Nieder C; Andratschke N; Jeremic B; Molls M
    Anticancer Res; 2003; 23(6D):5117-23. PubMed ID: 14981976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
    Muley T; Dienemann H; Ebert W
    Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients.
    Schneider J; Bitterlich N; Kotschy-Lang N; Raab W; Woitowitz HJ
    Anticancer Res; 2007; 27(4A):1869-77. PubMed ID: 17649786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.